



DEA TOX

DRUG ENFORCEMENT ADMINISTRATION
TOXICOLOGY TESTING PROGRAM

QUARTERLY REPORT

2026 Second Quarter



**U.S. Department of Justice
Drug Enforcement Administration
Diversion Control Division
Drug and Chemical Evaluation Section**

Table of Contents

Lists of Acronyms	3
Introduction.....	5
Summary	6
Novel Psychoactive Substances.....	7
Traditional Recreational Drugs	11
Over-the-Counter and Prescription Drugs	14
Dietary Supplement Stimulants	18
Precursors/Additives/Impurities	19
Drug Products.....	20
Contact Information	23
Public Domain Notice	24

List of Figures

Figure 1. Case Submissions By State.	6
Figure 2. Substance Detections by Category.	6
Figure 3. NPS Substance Detections.	7

List of Tables

Table 1. NPS Analytes Detected in Biological Samples.	8
Table 2. TRD Analytes Detected in Biological Samples.	11
Table 3. OTC/PD Analytes Detected in Biological Samples.	14
Table 4. DSS Analytes Detected in Biological Samples.	18
Table 5. P/A/I Detected in Biological Samples.....	19
Table 6. Drugs Detected in Drug Products.	20

Lists of Acronyms

Institutions and Programs

Acronym	Definition
CTEB	Clinical Toxicology and Environmental Biomonitoring
DEA	Drug Enforcement Administration
DEA TOX	Drug Enforcement Administration Toxicology Testing Program
UCSF	University of California, San Francisco

Drug Categories

Acronym	Definition
DSS	Dietary supplements
NPS	Novel psychoactive substances
OTC	Over-the-counter
P/A/I	Precursors, additives, or impurities
PD	Prescription drugs
TRD	Traditional recreational drugs

Sample-Related / Specimen Types

Acronym	Definition
NQ	Not quantified
DF	Decomposition fluid
GC	Gastric contents
LT	Liver tissue
MT	Muscle tissue
P	Plasma
S	Serum
U	Urine
WB	Whole blood

Units of Measurement

Acronym	Definition
g	Gram
mg	Milligram (1/1000th of a gram)
µg	Microgram (1/1000th of a milligram)
ng	Nanogram (1/1000th of a microgram)
mL	Milliliter

Localities Relevant to This Quarter

Acronym	Definition
U.S.	United States
FL	Florida
GA	Georgia
IL	Illinois
IN	Indiana
KS	Kansas
LA	Louisiana
MD	Maryland
MI	Michigan
MO	Missouri
NE	Nebraska
NM	New Mexico
OH	Ohio
OK	Oklahoma
PA	Pennsylvania
SC	South Carolina
TN	Tennessee
TX	Texas
UT	Utah

Common Substance Acronyms

Acronym	Definition
4-ANPP	4-Anilino- <i>N</i> -phenethylpiperidine
4-AP	4-Anilinopiperidine
EDDP	2-Ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine
EMDP	2-ethyl-5-methyl-3,3-diphenylpyrroline
<i>m</i> CPP	<i>meta</i> -Chlorophenylpiperazine
MGM-15	Dihydro-7-hydroxymitragynine
O-DSMT	O-Desmethyl- <i>cis</i> -tramadol
THC	Tetrahydrocannabinol

Introduction

The Drug Enforcement Administration Toxicology Testing Program (DEA TOX) began in May 2019 as a surveillance program aimed at detecting novel psychoactive substances (NPS) within the United States. In response to the ongoing synthetic drug epidemic, the Drug Enforcement Administration (DEA) awarded an agreement to the Clinical Toxicology and Environmental Biomonitoring (CTEB) Laboratory at the University of California, San Francisco (UCSF) to analyze biological samples—originating from drug related overdoses involving synthetic drugs—that DEA approves for submission by various stakeholders.

In many cases, the specific substance responsible for an overdose can be difficult to ascertain. The goal of DEA TOX is to connect symptom causation to the abuse of newly emerging synthetic drugs (e.g., synthetic cannabinoids, synthetic cathinones, synthetic opioids, other hallucinogens).

DEA TOX is interested in samples from patients thought to have ingested a synthetic drug, for which a drug screen produced little or no viable options to explain the symptoms exhibited by the patient (alcohol and THC are exempted). DEA TOX may approve testing of biological samples (blood preferred) from medical facilities, health departments, poison centers, law enforcement, or related institutions. On occasion, DEA TOX may approve non-biological samples. DEA TOX does not accept personal samples.

DEA covers the cost of analysis for each sample approved for testing. Requests for testing must be submitted directly to DEA TOX (DEATOX@DEA.GOV). Upon explicit approval of the request for testing of specific samples, the originating laboratory is invited to send their samples to the CTEB Laboratory at UCSF. The CTEB Laboratory uses liquid chromatography quadrupole time-of-flight mass spectrometry to confirm and quantify synthetic drugs identified within the samples. The CTEB Laboratory currently maintains a comprehensive drug library consisting of 1,418 drugs, of which 1,121 are NPS.

This publication presents the results of cases received and analyzed by the CTEB Laboratory during the second quarter [April 1–June 30] of 2026 (2026 Q2). These results are presented in tables throughout this document.

In these tables: If the frequency of detection for a substance is greater than one, the detected levels of that substance are denoted as a defined range that represents the low and high concentrations reported for that substance. In addition, the frequency refers to the number of cases in which an analyte was identified and includes the number of fatal cases in square brackets. For example, a frequency denoted as “12 [5]” refers to 12 total cases, of which 5 were fatal. Moreover, the number of cases originating from the participating states are indicated in parenthesis following the state abbreviation. For example, an annotation of “CA-2” under states found indicates that 2 of the relevant cases originated from California. Furthermore, any analytes denoted as an expected metabolite may also exist as a parent drug (i.e., may be administered directly) and do not indicate interpretations of results. Lastly, classifications for certain substances may evolve across reports to reflect updated information as more data are collected and evaluated.

Summary

During 2026 Q2, DEA TOX received and analyzed 173 samples from 166 cases originating from 18 states (Figure 1). These samples included 169 biological samples [8 serum, 154 whole blood, 5 urine, 1 muscle tissue (MT) and 1 gastric contents (GC)] and 4 drug products. Of these, 3 cases had multiple biological samples, 1 case had a drug product associated with a biological sample analyzed, and 1 case had three drug products associated with a biological sample.

DEA TOX analyzed these samples for NPS; traditional recreational drugs (TRD); over-the-counter (OTC) or prescription drugs (PD); dietary supplements (DSS); and precursors, additives, or impurities (P/A/I). DEA TOX did not detect analytes in two of these samples.

During 2026 Q2, DEA TOX reported a total of 1563 detections across biological and drug product samples (Figure 2A), spanning 147 distinct analytes (Figure 2B). While some identified drugs could be placed in multiple categories, for purposes of this report and for consistency, DEA TOX placed such substances in a single category only. Consequently, many PD that are commonly abused and encountered are listed as TRD. Substances that are not approved by the Food and Drug Administration for medical use within the United States are usually considered NPS.

Of the cases submitted this quarter, 82 (49.4%) of the 166 cases involved at least one NPS analyte. In addition, 51 (30.7%) of the 166 cases involved the detection of fentanyl.

Figure 2. Substance Detections by Category.





Figure 1. Case Submissions By State.

Novel Psychoactive Substances

DEA TOX confirmed 291 total detections (Figure 3A and Table 1) comprised of 34 NPS analytes from 7 different drug classes (Figure 3B) in 2026 Q2 biological samples. NPS detections in drug products are described in Table 6. Note: In this report, the Kratom Alkaloid designation includes dihydro-7-hydroxymitragynine (MGM-15) for streamlined reporting; MGM-15 does not naturally occur in the kratom plant.

Figure 3. NPS Substance Detections.




Table 1. NPS Analytes Detected in Biological Samples.

Drug Class	Analyte	Freq. [Fatal]	States Found	Reported Concentrations (ng/mL)				
				S	P	WB	U	GC
Amphetamine	Ethylamphetamine	1 [1]	TX			1.9		
Benzodiazepine	8-Amino Clonazepam**	2 [2]	IL-2			1.2–5.7		
	<i>Alpha</i> Hydroxy Bromazepam**	4 [4]	GA, IL, OK, TN	6.8		1.7–27.6		
	Bromazepam	6 [6]	GA, IL, SC, TN-3	31.2		0.1–75.4		
	Ethylbromazepam	1 [1]	TN			7.6		
	Etizolam	1 [1]	IL			6.1		
	Flualprazolam	1 [1]	IL			1.9		
	Flubromazepam	1 [1]	IL			18.6		
	Flubromazepam	1 [1]	IL			2.5		
	Phenazepam	7 [7]	OK, TN-6			0.7–11.2	5.6	
Benzofuran	5-APB	1 [1]	OK			107		
	5-MAPB	1 [1]	OK			4240		
Cannabinoid	11-nor-9-Carboxy-Delta-8 THC**	1 [1]	TN			20.4		
	5F-ADB	1 [1]	TX			1		
	5F-ADB Acid Metabolite**	9 [9]	MD-4, OH-3, TN, TX			5.6–63.8		
	Delta-8-THC	1 [1]	TN			32		

**These compounds are expected metabolites of parent drugs, which are listed below:

Expected Metabolite	Parent Drug
8-Amino Clonazepam	Clonazepam
<i>Alpha</i> Hydroxy Bromazepam	Bromazepam

Expected Metabolite	Parent Drug
11-Nor-9-Carboxy-Delta-8 THC	Delta-8-THC
5F-ADB Acid Metabolite	5F-ADB

Table 1 (Continued). NPS Analytes Detected in Biological Samples.

Drug Class	Analyte	Freq. [Fatal]	States Found	Reported Concentrations (ng/mL)				
				S	P	WB	U	MT
Cannabinoid	MDMB-4en-PINACA	5 [5]	MD-4, TX			0.1–1		
	MDMB-4en-PINACA acid metabolite	7 [7]	MD-5, TN, TX			4.8–22.6		
Depressant	Xylazine	11 [10]	GA, NM, SC, TN-8	28.7		0.7–9.7		
Kratom Alkaloid	16-Carboxymitragynine**	18 [18]	FL-8, GA, MD-2, OH, OK, TN-4, TX	1.4		1.4–131		
	7-Hydroxy Mitragynine**	23 [22]	FL-8, MD-3, NE, OH, TN-8, TX-2			3.7–419	8760	NQ
	9-O-Desmethylnitragynine**	20 [19]	FL-8, MD-2, NE, OH, TN-7, TX			3.8–1060	22.5	
	Corynantheidine	19 [18]	FL-8, MD-3, NE, OH, TN-5, TX			0.6–66.6		
	Dihydro-7-Hydroxy Mitragynine	20 [19]	FL-7, MD-3, NE, OH, TN-6, TX-2			0.7–1520	54.2	NQ
	Mitragynine	27 [26]	FL-8, GA, MD-3, NE, OH, OK, TN-10, TX-2	0.7		1.9–6660	36.8	
	Mitragynine Pseudoindoxyl**	25 [24]	FL-8, MD-3, NE, OH, OK, TN-9, TX-2			1.3–611	690	NQ
	Paynantheine	14 [14]	FL-8, MD, OH, TN-3, TX			2.4–915		
	Speciociliatine	18 [18]	FL-7, MD-3, OH, TN-6, TX			1.4–1620		

** These compounds are expected metabolite of parent drugs, which are listed below. However, some of these compounds may also be synthesized for kratom related products and ingested directly.

Expected Metabolite	Parent Drug
MDMB-4en-PINACA acid metabolite	MDMB-4-en-PINACA
16-Carboxymitragynine	Mitragynine
7-Hydroxy Mitragynine	Mitragynine

Expected Metabolite	Parent Drug
9-O-Desmethylnitragynine	Mitragynine
Mitragynine Pseudoindoxyl	Mitragynine / 7-Hydroxymitragynine

Table 1 (Continued). NPS Analytes Detected in Biological Samples.

Drug Class	Analyte	Freq. [Fatal]	States Found	Reported Concentrations (ng/mL)				
				S	P	WB	U	MT
Novel Synthetic Opioid	5,6-Dichloro Nor-Orphine	1 [1]	IL			1.8		
Novel Synthetic Opioid	5-Chloro Desmethyl Chlorphine	6 [6]	TN-6			0.9–544		
Novel Synthetic Opioid	<i>N</i> -Propionitrile Chlorphine	23 [23]	GA, IL-5, OK-2, SC-2, TN-13	1.8		0.3–6.7	7.4	
Novel Synthetic Opioid	<i>ortho</i> -Methylfentanyl	5 [5]	TN-5			0.3–3.2		
Novel Synthetic Opioid	<i>ortho</i> -Methylnorfentanyl**	3 [3]	TN-3			0.8–3.1		NQ
Novel Synthetic Opioid	<i>para</i> -Fluorofentanyl	3 [3]	GA, TN, UT	0.4		1.5–3.3		

** These compounds are expected metabolite of parent drugs, which are listed below:

Expected Metabolite	Parent Drug
ortho-Methylnorfentanyl	ortho-Methylfentanyl

Expected Metabolite	Parent Drug
5,6-Dichloro Nor-Orphine	5,6-Dichloro-Orphine

Traditional Recreational Drugs

DEA TOX confirmed 549 detections of 23 TRD analytes (Table 2) in biological samples in 2026 Q2.

Table 2. TRD Analytes Detected in Biological Samples.

Drug Class	Analyte	Freq.	States Found	Reported Concentrations (ng/mL)				
				S	P	WB	U	MT
Amphetamine	4-Hydroxy Methamphetamine**	1	SC			9.8		
	Amphetamine	42	FL-2, IL, LA, MD, NE-3, NM-2, OH, OK, SC-6, TN-21, TX-2, UT			1.9–1590	13800–13900	
	Methamphetamine	53	FL-2, GA, LA-3, MD-4, NE-4, NM-3, OK, SC-6, TN-26, TX-2, UT	0.9–369		0.3–22300	503–262000	NQ
	<i>N,N</i> -dimethylamphetamine	15	NE-2, NM, SC-4, TN-7, TX			0.5–17	1320–10600	
Arylcyclohexylamine	Ketamine	5	LA, NM-2, TN-2			1–5490		
	Norketamine**	5	LA, NM-2, TN-2			0.8–433		
Cannabinoid	11-nor-9-Carboxy-Delta-9 THC**	11	FL-2, MD-2, OH, OK, SC-2, TN-2, UT			25.7–5190		
	Delta-9-THC	5	FL, IL, MD, TX, UT			6.2–29.4		
Cocaine	Benzoylecgonine**	48	FL, GA-2, IL-4, KS, LA-2, MD-7, NE-2, NM-2, OK-2, PA, SC-9, TN-14, TX	6.8–765		0.3–8390	12.8–1050000	

** These compounds are expected metabolite of parent drugs, which are listed below:

Expected Metabolite	Parent Drug
4-Hydroxy Methamphetamine	Methamphetamine
Norketamine	Ketamine

Expected Metabolite	Parent Drug
11-Nor-9-Carboxy-Delta-9 THC	Delta-9-THC
Benzoylecgonine	Cocaine

Table 2 (Continued). TRD Analytes Detected in Biological Samples.

Drug Class	Analyte	Freq.	States Found	Reported Concentrations (ng/mL)				
				S	P	WB	U	MT
Cocaine	Cocaethylene	10	MD, NE, OK, PA, SC-5, TN			NQ		
	Cocaine	23	FL, GA, IL, MD, NE, NM, OK, PA, SC-6, TN-9	4.1		0.2–91.5		
	Ecgonine Methyl Ester**	23	FL, GA-2, IL, KS, MD, NE, NM, OK, PA, SC-8, TN-5	NQ		NQ	NQ	
Opioid	Codeine	2	MD-2			8.1–92.1		
	Fentanyl	51	GA-3, IL-2, KS, LA-2, MD-3, NE, NM-5, SC-6, TN-26, TX, UT	2.5–52.8		0.5–162	205	NQ
	Hydrocodone	6	GA-2, LA, MD, NM, SC	7.2–18.9		2.5–3240		
	Hydromorphone**	1	SC			7		
	Morphine	2	IL, LA			19.5–369		
	Norfentanyl**	46	FL, GA-2, IL-3, KS, LA, MD-2, NE, NM-5, SC-4, TN-24, TX, UT	1.1–127		0.2–13.8	3–1390	
	O-Desmethyl- <i>cis</i> -tramadol (O-DSMT)**	1	MD			0.2		
	Oxycodone	7	FL, IL-2, MD, OK, TN, UT			0.8–346		

** These compounds are expected metabolite of parent drugs, which are listed below:

Expected Metabolite	Parent Drug
Cocaethylene	Cocaine and Ethanol
Ecgonine Methyl Ester	Cocaine
Hydromorphone	Hydrocodone

Expected Metabolite	Parent Drug
Norfentanyl	Fentanyl
O-DSMT	Tramadol

Table 2 (Continued). TRD Analytes Detected in Biological Samples.

Drug Class	Analyte	Freq.	States Found	Reported Concentrations (ng/mL)				
				S	P	WB	U	MT
Opioid	Tramadol	5	FL, MD, SC, TN-2			0.3–0.7		
Stimulant	Cotinine**	116	FL-9, GA-3, IL-8, IN, KS-2, LA-5, MD-10, MI, NE-6, NM-4, OH-3, OK-2, PA, SC-12, TN-41, TX-5, UT-3	NQ		NQ	NQ	NQ
	Nicotine	68	FL-5, IL-4, LA-3, MD-6, NE-4, NM-2, OH, OK, PA, SC-8, TN-26, TX-5, UT-2			NQ	NQ	

** These compounds are expected metabolite of parent drugs, which are listed below:

Expected Metabolite	Parent Drug
Cotinine	Nicotine

Over-the-Counter and Prescription Drugs

DEA TOX confirmed 516 detections of 78 OTC/PD analytes (Table 3) in biological samples in 2026 Q2. OTC/PD were not detected in drug products, thus not described in Table 6. OTC/PD detections are not typically quantitated unless specifically requested; thus, reported concentration ranges are not provided.

Table 3. OTC/PD Analytes Detected in Biological Samples.

Drug Class	Drug	Freq.	States Found
Analgesic	Acetaminophen	37	FL, GA-2, IL-2, LA-3, MD-4, NE-2, NM-2, OH, OK, SC-2, TN-15, UT-2
	Naproxen	6	LA, MD, OH, SC-2, TN
Anesthetic	3-Hydroxy Medetomidine**	1	TX
	Lidocaine	26	FL, GA-3, LA-2, NE, NM-2, PA, SC-5, TN-9, TX, UT
	Medetomidine	7	IL, NM, TN-5
Antibiotic	Linezolid	1	MD
	Sulfamethoxazole	1	FL, GA-2, IL-2, LA-3, MD-4, NE-2, NM-2, OH, OK, SC-2, TN-15, UT-2
Anticoagulant	Warfarin	1	FL
Anticonvulsant	Carbamazepine	4	MD, OH, SC, TN
	Gabapentin	23	FL-3, IL, LA, MD-2, SC, TN-14, UT
	Lamotrigine	6	GA, OH, SC, TN-2, UT
	Levetiracetam	3	MD, OH, TN
	Oxcarbazepine	3	OH, SC, TN
	Phenytoin	1	MD
	Pregabalin	1	MD
	Topiramate	3	LA, MD, OH
Antidepressant	Amitriptyline	7	GA, MD, SC, TN-4
	Bupropion	4	FL, OH, TN, UT
	Citalopram	6	IL, KS, MD, SC, TN-2
	Fluoxetine	4	MD-2, SC, TN
	<i>m</i> CPP**	13	FL, GA, IL, MD, OH, SC-2, TN-5, UT
	Mirtazapine	6	MD, SC, TN-4

**Compounds are expected metabolites of parent drugs, as follows:

Expected Metabolite	Parent Drug
3-Hydroxy Medetomidine	Medetomidine

Expected Metabolite	Parent Drug
<i>m</i> CPP	Trazodone

Table 3 (Continued). OTC/PD Analytes Detected in Biological Samples.

Drug Class	Drug	Freq.	States Found
Antidepressant	Norfluoxetine**	4	MD-2, SC, TN
	Nortriptyline**	8	GA, MD-3, SC, TN-3
	Paroxetine	1	TN
	Sertraline	8	FL, IL, MD, SC-2, TN-3
	Trazodone	13	FL, GA, IL, MD, OH, SC-2, TN-5, UT
	Venlafaxine	7	FL, MD-4, TN-2
Antidiabetic	Metformin	1	TN
Antidiarrheal	Loperamide	2	FL, MD
Antihistamine	Chlorpheniramine	2	MD, TX
	Diphenhydramine	35	FL-4, GA, IL-4, LA, MD-5, NE, NM, OH, OK, SC, TN-15
	Doxylamine	6	IL-2, TN-3, TX
	Hydroxyzine	11	FL, GA, IL, KS, LA, MD, OH, SC, TN-3
	Loratadine	4	SC, TN-2, UT
	Promethazine	5	FL-2, IL-2, OH
Antipsychotic	Aripiprazole	5	KS, LA, MD, MO, OH
	Haloperidol	3	LA, MD, SC
	Olanzapine	6	FL, MD, OH, SC, TN-2
	Quetiapine	8	FL-2, MD, SC, TN-4
	Risperidone	3	LA, MD, SC
Antiretroviral	Emtricitabine	1	IL
Antitussive	Dextromethorphan	8	GA, IL, OK, SC-2, TN-3
	Dextrophan**	4	GA, IL, OK, TN
Anxiolytic	Buspirone	3	OH, TN-2
Benzodiazepine	7-Amino Clonazepam**	13	FL-4, IL-2, MD, NE, NM, OK, TN-3

**Compounds are expected metabolites of parent drugs, as follow:

Expected Metabolite	Parent Drug
Norfluoxetine	Fluoxetine
Nortriptyline	Amitriptyline

Expected Metabolite	Parent Drug
Dextrophan	Dextromethorphan
7-Amino Clonazepam	Clonazepam

Table 3 (Continued). OTC/PD Analytes Detected in Biological Samples.

Drug Class	Drug	Freq.	States Found
Benzodiazepine	Alpha Hydroxy Alprazolam**	9	GA, IL-2, NE, OK, TN-2, TX-2
	Alpha Hydroxy Midazolam**	4	GA, IL, LA, NM
	Alprazolam	22	FL-2, GA-2, IL-3, LA, MD-2, NE, NM, OK, TN-6, TX-2, UT
	Chlordiazepoxide	1	MD
	Clonazepam	2	FL, NE
	Diazepam	8	FL, IL, MD, SC-2, TN-3
	Lorazepam	4	MD, NM, SC, UT
	Midazolam	3	GA, LA, NM
	Nordiazepam**	7	IL, MD, SC-3, TN-2
	Oxazepam**	2	FL, MD
	Temazepam**	2	FL, SC
Bronchodilator	Albuterol	1	OH
Cardiovascular	Amiodarone	6	FL, MD, OK, PA, SC, TN
	Atropine	6	LA-2, MD, NM, TN-2
	Carvedilol	2	TN-2
	Clonidine	3	FL, MD, TN
	Metoprolol	5	OH, SC
Decongestant	Pseudoephedrine	1	LA-2, SC, TN-2
Diuretic	Furosemide	1	FL
	Hydrochlorothiazide	2	UT
Muscle Relaxant	Baclofen	1	MD
	Cyclobenzaprine	5	FL
	Methocarbamol	5	MD, SC, TN-3

**Compounds are expected metabolites of parent drugs, as listed below:

Expected Metabolite	Parent Drug
Alpha Hydroxy Alprazolam	Alprazolam
Alpha Hydroxy Midazolam	Midazolam
Nordiazepam	Diazepam

Expected Metabolite	Parent Drug
Oxazepam	Diazepam
Temazepam	Diazepam

Table 3 (Continued). OTC/PD Analytes Detected in Biological Samples.

Drug Class	Drug	Freq.	States Found
Opioid	Buprenorphine	4	KS, MD, NM, OK
	EDDP**	8	IL-2, MD-2, NE, TN-3
	EMDP**	2	IL, MD
	Methadone	10	IL-2, MD-2, NE, TN-5
	Norbuprenorphine**	2	KS, MD
Opioid Antagonist	Naloxone	47	FL-2, GA, IL, LA, MD-5, MO, NE-3, NM-5, OH-6, OK-2, PA, SC, TN-14, TX-2, UT-2
Paralytic	Rocuronium	7	IL, LA, NM-2, OH, OK, TN
Sedative	Zolpidem	3	OH, UT
	Zopiclone	1	TN

**Compounds are expected metabolites of parent drugs, as listed below:

Expected Metabolite	Parent Drug
EDDP	Methadone
EMDP	

Expected Metabolite	Parent Drug
Norbuprenorphine	Buprenorphine

Dietary Supplements

DEA TOX confirmed 132 detections of 2 DSS analytes (Table 4) in biological samples in 2026 Q2. One DSS was detected in a drug product, described in Table 6.

Table 4. DSS Analytes Detected in Biological Samples.

Analyte	Freq.	States Found
Caffeine	129	FL-10, GA-4, IL-4, IN, KS-2, LA-7, MD-13, MI, MO, NE-5, NM-6, OH-9, OK-3, PA, SC-11, TN-44, TX-3, UT-4
Melatonin	2	FL, MD

Precursors/Additives/Impurities

DEA TOX confirmed 71 detections of 10 P/A/I analytes (Table 5) in biological samples in 2026 Q2. P/A/I were not detected in drug products this quarter, thus not described in Table 6.

Table 5. P/A/I Detected in Biological Samples.

Drug Class	Analyte	Freq.	States Found	Reported Concentrations (ng/mL)				
				S	P	WB	U	GC
Additive	Levamisole	5	FL, NM, SC-2, TN			1–15		
	Phenacetin	1	TN			1		
	Quinine	18	IL-2, MD, OK, SC-2, TN-12			0.5–3320		
Impurity	<i>N</i> -Ethylmethamphetamine	1	SC				7.3	
Precursor	4-ANPP	37	GA-2, IL, KS, LA, MD, NE, NM-5, SC-5, TN-18, TX, UT	0.4–1		0.1–14.6	6	
	4-AP	1	TN			0.6		
	Despropionyl <i>para</i> -Fluorofentanyl	1	UT			0.4		
	Despropionyl- <i>ortho</i> -Methylfentanyl	4	TN-4			0.1–1		
	<i>N</i> -methyl Norfentanyl	1	NE			0.4		
	Tetramethyl-4-AP	2	SC, TN			0.8–1.4		

Drug Products

DEA TOX confirmed 4 detections of 2 analytes (Table 6) in 4 drug product samples analyzed in 2026 Q2.

Table 6. Drugs Detected in Drug Products.

Drug Category	Drug Class	Analyte	Freq.	States Found	Total Amounts in Drug Product*
NPS	Opioid	<i>N</i> -Propionitrile Chlorphine	3	SC	102–289 µg
DSS	Hormone	Melatonin	1	UT	3.4 mg

* Range (low to high) of the total amount within drug product.

Select Drug Product Exhibit:

Table 7. Drug Product Exhibit #1:

Total Exhibit Weight: 113.0 mg

Drug Category	Analyte	State Found	Reported Level	Total Amount within Drug Product
NPS	<i>N</i> -Propionitrile Chlorphine	SC	2.56 mg/g	289 µg





Table 8. Drug Product Exhibit #2:

Total Exhibit Weight: 361.7 mg

Drug Category	Analyte	State Found	Reported Level	Total Amount within Drug Product
DSS	Melatonin	UT	9.3 mg/g	3.4 mg



Contact Information

We invite medical and law enforcement facilities to contact our program if you encounter an overdose of a suspected synthetic drug and desire to have any leftover biological samples (blood preferred) analyzed further for such synthetic substances.

- **Sample Qualifications:**

- Patients thought to have ingested a synthetic drug, where the traditional drug screen has produced little or no viable options to explain the symptoms exhibited by the patient (alcohol and THC are exempted).

- **How to Contact Us and Send Your Samples:**

- Once the above qualifications are satisfied:
 - Email DEATOX@DEA.GOV with a brief description of the case (including initial toxicology screen and history) and a request for testing.
 - DEA will respond to each inquiry and, if approved, will send the instructions for packing and shipping of sample(s) to UCSF.
 - The main reason for disapproval of a case would be the identification of substances (including methamphetamine, heroin, fentanyl, cocaine, LSD, PCP, etc.) in a routine toxicology screening at your facility.
 - This program's goal is to connect symptom causation to abuse of newly emerging synthetic drugs (e.g., synthetic cannabinoids, synthetic cathinones, fentanyl-related substances, other hallucinogens).
- Ensure that you de-identify and label the sample with a numerical value, sex, date of birth or age, and the date and time the sample was collected in accordance with the labeling instructions (sent with shipping instructions).
- Keep a master list of the patients and the numerical values you allocated to each sample at your institution.

- **Cost of Sample Analysis:**

- DEA will cover the full cost of testing the patient samples.
 - The sender will only be responsible for paying for packing and shipping samples to UCSF.

- **Turn-around Time:**

- Results are expected within three to four weeks of receipt of the sample at UCSF except in rare occurrences when a novel substance is identified.

Public Domain Notice

All material appearing in this publication is in the public domain and may be reproduced or copied without permission from DEA. However, this publication may *not* be reproduced or distributed for a fee without the specific, written authorization of the Drug Enforcement Administration, U.S. Department of Justice. Citation of the source is appreciated.

Suggested citation:

U.S. Drug Enforcement Administration, Diversion Control Division (2026). *DEA TOX: Quarterly Report – Second Quarter 2026*. Springfield, VA.

OBTAINING COPIES OF THIS PUBLICATION

Electronic copies of this publication can be downloaded from the DEA TOX website at:

https://www.deadiversion.usdoj.gov/dea_tox/index.html.

This report was produced in conjunction with the CTEB Laboratory at UCSF.



**Clinical Toxicology
and Environmental Biomonitoring Laboratory**

DEA PRB-2026-237